Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation

Alvarado LJ, Huntsman HD, Cheng H, et al., 2019. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood, 133(19):2043–2055. https://doi.org/10.1182/blood-2018-11-884486

Bao WL, Bussel JB, Heck S, et al., 2010. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 116(22):4639–4645. https://doi.org/10.1182/blood-2010-04-281717

Bathini S, Holtzman NG, Koka R, et al., 2019. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol, 94(8):E216–E219. https://doi.org/10.1002/ajh.25515

Busca A, Dellacasa C, Giaccone L, et al., 2018. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 24(8):1765–1770. https://doi.org/10.1016/j.bbmt.2018.04.022

Desmond R, Townsley DM, Dumitriu B, et al., 2014. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 123(12):1818–1825. https://doi.org/10.1182/blood-2013-10-534743

Gao F, Zhou XY, Shi JM, et al., 2020. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol, 99(11):2679–2687. https://doi.org/10.1007/s00277-020-04106-2

Guenther KL, Cheruku PS, Cash A, et al., 2019. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol, 73:1–6.e6. https://doi.org/10.1016/j.exphem.2019.03.002

Hirokawa M, Fukuda T, Ohashi K, et al., 2013. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant, 19(7):1026–1032. https://doi.org/10.1016/j.bbmt.2013.04.004

Olnes MJ, Scheinberg P, Calvo KR, et al., 2012. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med, 367(1):11–19. https://doi.org/10.1056/NEJMoa1200931

Sackett K, Cohn CS, Fahey-Ahrndt K, et al., 2018. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher, 33(1):108–112. https://doi.org/10.1002/jca.21553

Selleri C, Raiola A, de Rosa G, et al., 1998. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant, 22(6):605–607. https://doi.org/10.1038/sj.bmt.1701384

Shahan JL, Hildebrandt GC, 2015. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med, 25(5):342–344. https://doi.org/10.1111/tme.12216

Vlachodimitropoulou E, Chen YL, Garbowski M, et al., 2017. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 130(17):1923–1933. https://doi.org/10.1182/blood-2016-10-740241

Yang X, Levis M, 2014. Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation. Transfus Med, 24(4):246–248. https://doi.org/10.1111/tme.12143

Zhao Z, Sun Q, Sokoll LJ, et al., 2018. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood, 131(21):2399–2402. https://doi.org/10.1182/blood-2018-01-826784

Zhidong W, Hongmin Y, Hengxiang W, 2012. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med, 22(4):302–304. https://doi.org/10.1111/j.1365-3148.2012.01156.x